A preclinical study unexpectedly identified the gene Foxo1 as a potential treatment target for hereditary lymphedema. Valve loss or dysfunction that disrupts the flow of lymph fluid is strongly associated with lymphedema in patients. But no one has discovered whether new valves can be grown or if defective ones can be fixed. The new study, using a model of human primary lymphedema, shows that both are possible.
from Top Health News -- ScienceDaily https://ift.tt/3CwyC4l
Post a Comment